Skip to Content Facebook Feature Image

Lawsuit against UK security agency by survivors of Ariana Grande concert bombing is rejected

ENT

Lawsuit against UK security agency by survivors of Ariana Grande concert bombing is rejected
ENT

ENT

Lawsuit against UK security agency by survivors of Ariana Grande concert bombing is rejected

2024-11-22 22:44 Last Updated At:22:51

LONDON (AP) — A legal claim against Britain’s domestic intelligence agency by more than 300 survivors of a bombing that killed 22 people at a 2017 Ariana Grande concert in Manchester was rejected Friday by a special tribunal.

Judges on the U.K.’s Investigatory Powers Tribunal said the claimants waited too long to bring their case, which alleged that MI5 violated their human rights by failing to take measures that could have prevented the disaster.

Suicide bomber Salman Abedi set up a knapsack bomb in Manchester Arena at the end of Grande's concert on May 22, 2017, as thousands of young fans were leaving. As well as the 22 dead, more than 100 people were injured, many of them children and teenagers. Abedi died in the explosion.

An official inquiry reported last year that MI5 didn’t act swiftly enough on key information and missed a significant opportunity to prevent the bombing, the deadliest extremist attack in the U.K. in recent years.

Abedi had been a “subject of interest” to MI5 officials in 2014, but his case was closed shortly after because he was deemed to be low risk.

The report also found one MI5 officer considered intelligence about Abedi to be a possible national security concern, but didn’t discuss it with colleagues quickly enough.

Ken McCallum, the head of MI5, said in a rare televised statement that he was “profoundly sorry” his agency was unable to prevent the attack.

Justice Rabinder Singh said the tribunal was “conscious of the horrendous impact of the atrocity” on the victims but said it would not be fair to let the claims proceed when they could have been filed sooner.

“Any reasonable person would have sympathy for them," Singh said. “The grief and trauma which they have suffered, particularly where young children were killed, is almost unimaginable."

Singh also noted that if the case had proceeded it would have taken MI5 away from its core mission.

Three law firms representing the victims said in a statement that the ruling was “extremely disappointing.”

"Our clients have had to endure continued delays but have done so with great patience and understanding in the hope that by allowing all legal processes to be fully explored, transparency and justice would be achieved,” the statement said.

FILE - A man stands next to flowers for the victims of a bombing at St. Ann's Square in central Manchester, England, May 26, 2017. (AP Photo/Emilio Morenatti, File)

FILE - A man stands next to flowers for the victims of a bombing at St. Ann's Square in central Manchester, England, May 26, 2017. (AP Photo/Emilio Morenatti, File)

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Jan 12, 2026--

ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market. To support its growth in the region, ChemWerth has hired Chandrakanth Reddy as general sales manager of its India office.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260111302280/en/

“The addition of a general sales manager in India signals our desire to grow our presence and customer base in the world’s most important generic pharmaceutical market,” said Pete Werth III, president, ChemWerth. “Chandrakanth will add tremendous value for our customers and contract manufacturing organizations (CMOs) in India.”

Reddy is a seasoned pharmaceutical professional with more than 16 years of experience spanning API sourcing, business development, market expansion and regulatory-driven commercial strategy. He has successfully led high-value markets across India, the Middle East, North Africa, Europe, and the United States, building strong customer partnerships and supporting sustainable revenue growth.

In his new role, Reddy will be responsible for leading ChemWerth’s sales strategy in India and strengthening regional customer relationships. He will also support the company’s focused initiative to roll out new generic APIs in the market, including fermentation, peptide and oncology injectable APIs.

“After reviewing ChemWerth’s strategic plan to unveil a strong pipeline of new generic fermentation, peptide and oncology injectable APIs for the Indian market, I knew that was something I wanted to be a part of,” said Reddy.

About ChemWerth, Inc.:

Established in 1982, ChemWerth is a full-service generic active pharmaceutical ingredient (API) development and supply company providing cGMP-quality APIs to regulated markets worldwide. ChemWerth is a global company headquartered in the United States, with offices in China and India. For more information, please visit www.chemwerth.com.

Chandrakanth Reddy has joined ChemWerth, Inc., as general sales manager of its India office.

Chandrakanth Reddy has joined ChemWerth, Inc., as general sales manager of its India office.

Recommended Articles